The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Alzheimer's and Dementia

Volumn 11, Issue 7, 2015, Pages 772-791

  Kang, Ju Hee ^a,b   Korecka, Magdalena ^a   Figurski, Michal J ^a   Toledo, Jon B ^a   Blennow, Kaj ^c   Zetterberg, Henrik ^c,d   Waligorska, Teresa ^a   Brylska, Magdalena ^a   Fields, Leona ^a   Shah, Nirali ^a   Soares, Holly ^e   Dean, Robert A ^f   Vanderstichele, Hugo ^g   Petersen, Ronald C ^h   Aisen, Paul S ⁱ   Saykin, Andrew J ^j   Weiner, Michael W ^k,l   Trojanowski, John Q ^a,m   Shaw, Leslie M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inha University School of Medicine   (South Korea)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e BRISTOL MYERS SQUIBB   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g Rogers BVBA   (Belgium)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

ADNI; Alzheimer's disease; A 1 42; Biomarkers; Cerebrospinal fluid; Disease modifying therapy; Immunoassay; Mild cognitive impairment; Plasma; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; BIOLOGICAL MARKER; CHEMOKINE; CYSTATIN C; CYTOKINE; EOTAXIN 3; FIBRINOGEN; FLORBETAPIR F 18; GROWTH FACTOR; HEMOGLOBIN A; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; NEUROGRANIN; PANCREAS POLYPEPTIDE; PENTAXIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SECRETOGRANIN II; SOMATOMEDIN BINDING PROTEIN 2; STROMELYSIN 2; SUPEROXIDE DISMUTASE; TAR DNA BINDING PROTEIN; TAU PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; VASCULOTROPIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTOPSY; CELL DEATH; CEREBROSPINAL FLUID ANALYSIS; CHEMILUMINESCENCE ANALYZER; DATA PROCESSING; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; ELISA KIT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETER; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HEREDITY; HIPPOCAMPAL SCLEROSIS; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; IMMUNOBLOTTING; INFLAMMATION; LEWY BODY; MICROPLATE READER; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEOMICS; PUBLICATION; RESEARCH DIAGNOSTIC CRITERIA; RESOURCE ALLOCATION; REVIEW; SHY DRAGER SYNDROME; TANDEM MASS SPECTROMETRY; TDP 43 PROTEINOPATHY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BIBLIOGRAPHIC DATABASE; CEREBROSPINAL FLUID; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DATABASES, BIBLIOGRAPHIC; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84937548717     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.05.003     Document Type: Review

References (127)

1. J.A. Schneider, Z. Arvanitakis, W. Bang, and D.A. Bennett Mixed brain pathologies account for most dementia cases in community-dwelling older persons Neurology 69 2007 2197 2204
2. L. White, B.J. Small, H. Petrovitch, G.W. Ross, K. Masaki, R.D. Abbott, and et al. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study J Geriatr Psychiatry Neurol 18 2005 224 227
3. T. Gomez-Isla, R. Hollister, H. West, S. Mui, J.H. Growdon, R.C. Petersen, and et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease Ann Neurol 41 1997 17 24
4. G.M. Savva, S.B. Wharton, P.G. Ince, G. Forster, F.E. Matthews, C. Brayne, and et al. Age, neuropathology, and dementia N Engl J Med 360 2009 2302 2309
5. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, and et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann Neurol 30 1991 572 580
6. P.T. Nelson, E.L. Abner, F.A. Schmitt, R.J. Kryscio, G.A. Jicha, C.D. Smith, and et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons Brain Pathol 20 2010 66 79
7. D.S. Knopman, J.E. Parisi, A. Salviati, M. Floriach-Robert, B.F. Boeve, R.J. Ivnik, and et al. Neuropathology of cognitively normal elderly J Neuropathol Exp Neurol 62 2003 1087 1095
8. J.L. Price, and J.C. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 1999 358 368
9. R.C. Petersen Mild cognitive impairment as a diagnostic entity J Intern Med 256 2004 183 194
10. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, and et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 2014 614 629
11. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, and et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
12. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, and et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
13. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, and et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
14. M. Maruyama, H. Shimada, T. Suhara, H. Shinotoh, B. Ji, J. Maeda, and et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls Neuron 79 2013 1094 1108
15. V.L. Villemagne, M.T. Fodero-Tavoletti, C.L. Masters, and C.C. Rowe Tau imaging: early progress and future directions Lancet Neurol 14 2015 114 124
16. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, R.C. Petersen, and et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
17. G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, P.P. De Deyn, and et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Arch Neurol 67 2010 949 956
18. H. Vanderstichele, M. Bibl, S. Engelborghs, N. Le Bastard, P. Lewczuk, J.L. Molinuevo, and et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative Alzheimers Dement 8 2012 65 73
19. M.C. Carrillo, K. Blennow, H. Soares, P. Lewczuk, N. Mattsson, P. Oberoi, and et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium Alzheimers Dement 9 2013 137 140
20. J.H. Kang, M. Korecka, J.B. Toledo, J.Q. Trojanowski, and L.M. Shaw Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers Clin Chem 59 2013 903 916
21. A. Olsson, H. Vanderstichele, N. Andreasen, G. De Meyer, A. Wallin, B. Holmberg, and et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin Chem 51 2005 336 345
22. M.J. Figurski, T. Waligórska, M. Brylska, M. Korecka, L. Fields, N. Shah, and et al. Prospective quality-control monitoring in the context of a clinical trial 2015 AAIC Washington, D.C
23. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, M. Figurski, E. Coart, K. Blennow, and et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI Acta Neuropathol 121 2011 597 609
24. A.M. Fagan, L.M. Shaw, C. Xiong, H. Vanderstichele, M.A. Mintun, J.Q. Trojanowski, and et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology Arch Neurol 68 2011 1137 1144
25. L.S. Wang, Y.Y. Leung, S.K. Chang, S. Leight, M. Knapik-Czajka, Y. Baek, and et al. Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease J Alzheimers Dis 31 2012 439 445
26. D.J. Irwin, C.T. McMillan, J.B. Toledo, S.E. Arnold, L.M. Shaw, L.S. Wang, and et al. Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms Arch Neurol 69 2012 1018 1025
27. P. Lewczuk, G. Beck, O. Ganslandt, H. Esselmann, F. Deisenhammer, A. Regeniter, and et al. International quality control survey of neurochemical dementia diagnostics Neurosci Lett 409 2006 1 4
28. N.A. Verwey, W.M. van der Flier, K. Blennow, C. Clark, S. Sokolow, P.P. De Deyn, and et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem 46 2009 235 240
29. M. Vandijck, R. Kuwano, T. Waligorska, S. De Smet, T. Tsukie, L. Verdoodt, and et al. Inter-laboratory variation when using a unified test procedure for INNO-BIA AlzBio3 Alzheimers Dement 9 Supplement 4 2013 P209 P210
30. M.J. Figurski, T. Waligorska, J. Toledo, H. Vanderstichele, M. Korecka, V.M. Lee, and et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients Alzheimers Dement 8 2012 250 260
31. H. Arai, M. Terajima, M. Miura, S. Higuchi, T. Muramatsu, N. Machida, and et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease Ann Neurol 38 1995 649 652
32. T. Sunderland, G. Linker, N. Mirza, K.T. Putnam, D.L. Friedman, L.H. Kimmel, and et al. Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease JAMA 289 2003 2094 2103
33. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613
34. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 2006 228 234
35. E. Vanmechelen, H. Vanderstichele, P. Davidsson, E. Van Kerschaver, B. Van Der Perre, M. Sjogren, and et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization Neurosci Lett 285 2000 49 52
36. S. Negash, S. Xie, C. Davatzikos, C.M. Clark, J.Q. Trojanowski, L.M. Shaw, and et al. Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology Alzheimers Dement 9 2013 e89 e95
37. J.B. Toledo, M. Bjerke, X. Da, S.M. Landau, N.L. Foster, W. Jagust, and et al. Nonlinear association between cerebrospinal fluid and florbetapir F-18 Aβ measures across the spectrum of Alzheimer's disease JAMA Neurol 72 2015 571 581
38. S.K. Herukka, M. Hallikainen, H. Soininen, and T. Pirttila CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment Neurology 64 2005 1294 1297
39. A.M. Fagan, C.M. Roe, C. Xiong, M.A. Mintun, J.C. Morris, and D.M. Holtzman Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 2007 343 349
40. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, M. Jonsson, and et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
41. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
42. F.H. Duits, C.E. Teunissen, F.H. Bouwman, P.J. Visser, N. Mattsson, H. Zetterberg, and et al. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimers Dement 10 2014 713 723.e2
43. S.M. Landau, M. Lu, A.D. Joshi, M. Pontecorvo, M.A. Mintun, J.Q. Trojanowski, and et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid Ann Neurol 74 2013 826 836
44. R. Dean, L.M. Shaw, T.W. Waligorska, M. Korecka, M. Figurski, J.Q. Trojonowski, and et al. Inclusion of patients with Alzheimer's disease pathology in solanezumab EXPEDITION 3 using florbetafir PET imaging or INNO-BIA AlzBio3 CSF Aβ1-42 Alzheimers Dement 10 Supplement 4 2014 P811
45. N. Mattsson, P.S. Insel, M. Donohue, W. Jagust, R. Sperling, P. Aisen, and et al. Predicting reduction of cerebrospinal fluid beta-amyloid 42 in cognitively healthy controls JAMA Neurol 72 2015 554 560
46. J.B. Toledo, N.J. Cairns, X. Da, K. Chen, D. Carter, A. Fleisher, and et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings Acta Neuropathol Commun 1 2013 65
47. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, R.C. Green, and et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 9 2013 e111 e194
48. J.B. Toledo, J. Brettschneider, M. Grossman, S.E. Arnold, W.T. Hu, S.X. Xie, and et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases Acta Neuropathol 124 2012 23 35
49. V.A. Guzman, O.T. Carmichael, C. Schwarz, G. Tosto, M.E. Zimmerman, A.M. Brickman, and et al. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment Alzheimers Dement 9 2013 S124 S131
50. M.I. Kester, J.D. Goos, C.E. Teunissen, M.R. Benedictus, F.H. Bouwman, M.P. Wattjes, and et al. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers JAMA Neurol 71 2014 855 862
51. J.B. Toledo, A. Korff, L.M. Shaw, J.Q. Trojanowski, and J. Zhang CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease Acta Neuropathol 126 2013 683 697
52. Y. Wang, M. Shi, K.A. Chung, C.P. Zabetian, J.B. Leverenz, D. Berg, and et al. Phosphorylated alpha-synuclein in Parkinson's disease Sci Transl Med 4 2012 121ra20
53. J.B. Toledo, S.X. Xie, J.Q. Trojanowski, and L.M. Shaw Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI Acta Neuropathol 126 2013 659 670
54. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, and et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
55. A. Caroli, G.B. Frisoni Alzheimer's Disease Neuroimaging Initiative The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort Neurobiol Aging 31 2010 1263 1274
56. L.A. Beckett, D.J. Harvey, A. Gamst, M. Donohue, J. Kornak, H. Zhang, and et al. The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes Alzheimers Dement 6 2010 257 264
57. R.Y. Lo, A.E. Hubbard, L.M. Shaw, J.Q. Trojanowski, R.C. Petersen, P.S. Aisen, and et al. Longitudinal change of biomarkers in cognitive decline Arch Neurol 68 2011 1257 1266
58. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, P.S. Aisen, and et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
59. K.B. Walhovd, A.M. Fjell, J. Brewer, L.K. McEvoy, C. Fennema-Notestine, D.J. Hagler Jr., and et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease AJNR Am J Neuroradiol 31 2010 347 354
60. I.A. van Rossum, S.J. Vos, L. Burns, D.L. Knol, P. Scheltens, H. Soininen, and et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology Neurology 79 2012 1809 1816
61. T.C. Durazzo, N. Mattsson, M.W. Weiner, M. Korecka, J.Q. Trojanowski, L.M. Shaw, and et al. History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress Drug Alcohol Depend 142 2014 262 268
62. M. Ewers, S. Schmitz, O. Hansson, C. Walsh, A. Fitzpatrick, D. Bennett, and et al. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease Neurobiol Aging 33 2012 1599 1608
63. L.B. Yang, K. Lindholm, R. Yan, M. Citron, W. Xia, X.L. Yang, and et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease Nat Med 9 2003 3 4
64. R. Li, K. Lindholm, L.B. Yang, X. Yue, M. Citron, R. Yan, and et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients Proc Natl Acad Sci U S A 101 2004 3632 3637
65. J.H. Verheijen, L.G. Huisman, N. van Lent, U. Neumann, P. Paganetti, C.E. Hack, and et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay Clin Chem 52 2006 1168 1174
66. Z. Zhong, M. Ewers, S. Teipel, K. Burger, A. Wallin, K. Blennow, and et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment Arch Gen Psychiatry 64 2007 718 726
67. C. Rosen, U. Andreasson, N. Mattsson, J. Marcusson, L. Minthon, N. Andreasen, and et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease Neuromolecular Med 14 2012 65 73
68. R. Perneczky, P. Alexopoulos Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease Alzheimers Dement 10 2014 S425 S429.e1
69. Savage MJ, Holder DJ,Wu G, Kaplow J, Siuciak JA, Potter WZ, et al. Soluble BACE-1 activity and sAPPb concentrations in AD and age-matched healthy control CSF from the Alzheimer's Disease Neuroimaging Initiative-1 baseline cohort. J Alzheimers Dis: http://dx.doi.org/10.3233/JAD-150290.
70. W.T. Hu, A. Chen-Plotkin, S.E. Arnold, M. Grossman, C.M. Clark, L.M. Shaw, and et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment Acta Neuropathol 119 2010 669 678
71. R. Craig-Schapiro, M. Kuhn, C. Xiong, E.H. Pickering, J. Liu, T.P. Misko, and et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis PLoS One 6 2011 e18850
72. R.W. Paterson, J.W. Bartlett, K. Blennow, N.C. Fox Alzheimer's Disease Neuroimaging Imaging L.M. Shaw, and et al. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals Transl Psychiatry 4 2014 e419
73. H.D. Soares, W.Z. Potter, E. Pickering, M. Kuhn, F.W. Immermann, D.M. Shera, and et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease Arch Neurol 69 2012 1310 1317
74. W.T. Hu, D.M. Holtzman, A.M. Fagan, L.M. Shaw, R. Perrin, S.E. Arnold, and et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease Neurology 79 2012 897 905
75. S.E. O'Bryant, G. Xiao, R. Barber, R. Huebinger, K. Wilhelmsen, M. Edwards, and et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI PLoS One 6 2011 e28092
76. J.S. Kauwe, M.H. Bailey, P.G. Ridge, R. Perry, M.E. Wadsworth, K.L. Hoyt, and et al. Genome-wide association study of CSF levels of 59 Alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation PLoS Genet 10 2014 e1004758
77. N. Mattsson, U. Andreasson, S. Persson, M.C. Carrillo, S. Collins, S. Chalbot, and et al. CSF biomarker variability in the Alzheimer's Association quality control program Alzheimers Dement 9 2013 251 261
78. M. Korecka, T. Waligorska, M. Figurski, J.B. Toledo, S.E. Arnold, M. Grossman, and et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta 42 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry J Alzheimers Dis 41 2014 441 451
79. A. Leinenbach, J. Pannee, T. Dulffer, A. Huber, T. Bittner, U. Andreasson, and et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid Clin Chem 60 2014 987 994
80. D.S. Spellman, K.R. Wildsmith, L.A. Honigberg, M. Tuefferd, D. Baker, N. Raghavan, and et al. Development and evaluation of a multiplexed mass spectrometry-based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF Proteomics Clin Appl 2015 10.1002/prca.201400178
81. E. Masliah, M. Mallory, M. Alford, R. DeTeresa, L.A. Hansen, D.W. McKeel Jr., and et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease Neurology 56 2001 127 129
82. S.W. Scheff, D.A. Price, F.A. Schmitt, S.T. DeKosky, and E.J. Mufson Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment Neurology 68 2007 1501 1508
83. P. Davidsson, and K. Blennow Neurochemical dissection of synaptic pathology in Alzheimer's disease Int Psychogeriatr 10 1998 11 23
84. A. Thorsell, M. Bjerke, J. Gobom, E. Brunhage, E. Vanmechelen, N. Andreasen, and et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease Brain Res 1362 2010 13 22
85. H. Kvartsberg, F.H. Duits, M. Ingelsson, N. Andreasen, A. Ohrfelt, K. Andersson, and et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease Alzheimers Dement 2014 10.1016/j.jalz.2014.10.009
86. D. Stephenson, E. Aviles, M. Brumfield, M.C. Carrillo, T.A. Compery, C. Compton, and et al. Coalition Against Major Disease; precompetitive collaborations and regulatory paths to accelerating drug development for neurodegenerative diseases Ther Innov Regul Sci 47 2013 632 638
87. M.E. Lame, E.E. Chambers, and M. Blatnik Quantitation of amyloid beta peptides Abeta(1-38), Abeta(1-40), and Abeta(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry Anal Biochem 419 2011 133 139
88. J. Pannee, E. Portelius, M. Oppermann, A. Atkins, M. Hornshaw, I. Zegers, and et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls J Alzheimers Dis 33 2013 1021 1032
89. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, K. Blennow, and et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 13 2007 1359 1362
90. J. Marksteiner, D. Imarhiagbe, M. Defrancesco, E.A. Deisenhammer, G. Kemmler, and C. Humpel Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study Exp Gerontol 50 2014 114 121
91. D.A. Llano, V. Devanarayan, and A.J. Simon Alzheimer's Disease Neuroimaging I. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease Alzheimer Dis Assoc Disord 27 2013 233 243
92. J.D. Doecke, S.M. Laws, N.G. Faux, W. Wilson, S.C. Burnham, C.P. Lam, and et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease Arch Neurol 69 2012 1318 1325
93. G. Wu, S. Sankaranarayanan, J. Wong, K. Tugusheva, M.S. Michener, X. Shi, and et al. Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease J Neurosci Res 90 2012 2247 2258
94. M. Thambisetty, A. Simmons, L. Velayudhan, A. Hye, J. Campbell, Y. Zhang, and et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease Arch Gen Psychiatry 67 2010 739 748
95. S.J. Kiddle, M. Sattlecker, P. Proitsi, A. Simmons, E. Westman, C. Bazenet, and et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study J Alzheimers Dis 38 2014 515 531
96. S. Kim, S. Swaminathan, M. Inlow, S.L. Risacher, K. Nho, L. Shen, and et al. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel PLoS One 8 2013 e70269
97. M. Britschgi, and T. Wyss-Coray Blood protein signature for the early diagnosis of Alzheimer disease Arch Neurol 66 2009 161 165
98. R. Mayeux, L.S. Honig, M.X. Tang, J. Manly, Y. Stern, N. Schupf, and et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk Neurology 61 2003 1185 1190
99. J.K. Lui, S.M. Laws, Q.X. Li, V.L. Villemagne, D. Ames, B. Brown, and et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging J Alzheimers Dis 20 2010 1233 1242
100. P.D. Mehta, T. Pirttila, S.P. Mehta, E.A. Sersen, P.S. Aisen, and H.M. Wisniewski Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch Neurol 57 2000 100 105
101. O. Hansson, H. Zetterberg, E. Vanmechelen, H. Vanderstichele, U. Andreasson, E. Londos, and et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment Neurobiol Aging 31 2010 357 367
102. P. Lewczuk, J. Kornhuber, E. Vanmechelen, O. Peters, I. Heuser, W. Maier, and et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing Exp Neurol 223 2010 366 370
103. O.I. Okereke, W. Xia, D.J. Selkoe, and F. Grodstein Ten-year change in plasma amyloid beta levels and late-life cognitive decline Arch Neurol 66 2009 1247 1253
104. K. Yaffe, A. Weston, N.R. Graff-Radford, S. Satterfield, E.M. Simonsick, S.G. Younkin, and et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline JAMA 305 2011 261 266
105. S.A. Cosentino, Y. Stern, E. Sokolov, N. Scarmeas, J.J. Manly, M.X. Tang, and et al. Plasma ss-amyloid and cognitive decline Arch Neurol 67 2010 1485 1490
106. J.B. Toledo, H. Vanderstichele, M. Figurski, P.S. Aisen, R.C. Petersen, M.W. Weiner, and et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI Acta Neuropathol 122 2011 401 413
107. J.B. Toledo, L.M. Shaw, and J.Q. Trojanowski Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Alzheimers Res Ther 5 2013 8
108. R.A. Rissman, J.Q. Trojanowski, L.M. Shaw, and P.S. Aisen Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease J Neural Transm 119 2012 843 850
109. M. Gatz, C.A. Reynolds, L. Fratiglioni, B. Johansson, J.A. Mortimer, S. Berg, and et al. Role of genes and environments for explaining Alzheimer disease Arch Gen Psychiatry 63 2006 168 174
110. A.L. Bergem, K. Engedal, and E. Kringlen The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study Arch Gen Psychiatry 54 1997 264 270
111. S. Swaminathan, S.L. Risacher, K.K. Yoder, J.D. West, L. Shen, S. Kim, and et al. Association of plasma and cortical amyloid beta is modulated by APOE epsilon4 status Alzheimers Dement 10 2014 e9 e18
112. D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M.L. Hamshere, and et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease Nat Genet 41 2009 1088 1093
113. J.C. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers, M. Hiltunen, and et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease Nat Genet 41 2009 1094 1099
114. G. Jun, A.C. Naj, G.W. Beecham, L.S. Wang, J. Buros, P.J. Gallins, and et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes Arch Neurol 67 2010 1473 1484
115. A.C. Naj, G. Jun, G.W. Beecham, L.S. Wang, B.N. Vardarajan, J. Buros, and et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet 43 2011 436 441
116. P. Hollingworth, D. Harold, R. Sims, A. Gerrish, J.C. Lambert, M.M. Carrasquillo, and et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Nat Genet 43 2011 429 435
117. K. Nho, J.J. Corneveaux, S. Kim, H. Lin, S.L. Risacher, L. Shen, and et al. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment Mol Psychiatry 18 2013 781 787
118. K. Nho, S. Kim, S.L. Risacher, L. Shen, J.J. Corneveaux, S. Swaminathan, and et al. Protective variant for hippocampal atrophy identified by whole exome sequencing Ann Neurol 77 2015 547 552
119. D. Kapogiannis, A. Boxer, J.B. Schwartz, E.L. Abner, A. Biragyn, U. Masharani, and et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease FASEB J 29 2015 589 596
120. M.S. Fiandaca, D. Kapogiannis, M. Mapstone, A. Boxer, E. Eitan, J.B. Schwartz, and et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study Alzheimers Dement 2014 10.1016/j.jalz.2014.06.008
121. K. Talbot, H.Y. Wang, H. Kazi, L.Y. Han, K.P. Bakshi, A. Stucky, and et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline J Clin Invest 122 2012 1316 1338
122. K. Henriksen, S.E. O'Bryant, H. Hampel, J.Q. Trojanowski, T.J. Montine, A. Jeromin, and et al. The future of blood-based biomarkers for Alzheimer's disease Alzheimers Dement 10 2014 115 131
123. S.E. O'Bryant, V. Gupta, K. Henriksen, M. Edwards, A. Jeromin, S. Lista, and et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research Alzheimers Dement 11 2015 549 560
124. J.Q. Trojanowski, H. Vandeerstichele, M. Korecka, C.M. Clark, P.S. Aisen, R.C. Petersen, and et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects Alzheimers Dement 6 2010 230 238
125. R. Lautner, S. Palmqvist, N. Mattsson, U. Andreasson, A. Wallin, E. Palsson, and et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease JAMA Psychiatry 71 2014 1183 1191
126. J.B. Toledo, X. Da, M.W. Weiner, D.A. Wolk, S.X. Xie, S.E. Arnold, and et al. CSF Apo-E levels associate with cognitive decline and MRI changes Acta Neuropathol 127 2014 621 632
127. N. Le Bastard, P.P. De Deyn, and S. Engelbourghs Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid Clin Chem 61 2015 734 743